Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Treasury Shares (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Treasury Shares for 12 consecutive years, with $10.7 million as the latest value for Q1 2021.

  • On a quarterly basis, Treasury Shares changed 0.0% to $10.7 million in Q1 2021 year-over-year; TTM through Mar 2021 was $10.7 million, a 0.0% change, with the full-year FY2020 number at $10.7 million, changed 0.0% from a year prior.
  • Treasury Shares was $164080.0 for Q3 2025 at Harvard Bioscience, down from $432521.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $7.7 million in Q1 2021 to a low of $164080.0 in Q3 2025.
  • A 5-year average of $1.6 million and a median of $1.2 million in 2023 define the central range for Treasury Shares.
  • Biggest YoY gain for Treasury Shares was 0.0% in 2017; the steepest drop was 0.0% in 2017.
  • Harvard Bioscience's Treasury Shares stood at $10.7 million in 2017, then changed by 0.0% to $10.7 million in 2018, then changed by 0.0% to $10.7 million in 2019, then changed by 0.0% to $10.7 million in 2020, then changed by 0.0% to $10.7 million in 2021.
  • Per Business Quant, the three most recent readings for HBIO's Treasury Shares are $10.7 million (Q1 2021), $10.7 million (Q4 2020), and $10.7 million (Q3 2020).